Impact of Electronic Prescribing of Controlled Substances on Opioid Prescribing: Evidence From I-STOP Program in New York

Abstract

New York’s Internet System for Tracking Over-Prescribing (I-STOP) Act, requires prescribers in the state to electronically prescribe controlled substances (EPCS). We examine the effects of this mandate on prescribing patterns of opioids for Medicare Part D beneficiaries. Using 2014-2017 CMS Medicare Part D Prescriber Data, we apply a lagged dependent variable regression approach to identify the impact of I-STOP on the prescription of opioids. In the first year of implementation, the number of opioid prescriptions per prescriber decreased by 5.7 per year. The policy had a larger effect on the prescription of short-acting opioids and on prescribers prescribing medication for predominantly younger beneficiaries. Overall, I-STOP resulted in a reduction in the number of beneficiaries being prescribed opioids and in the number of opioid claims in the state of New York, suggesting positive implications for other states intending to curtail opioid overprescribing and misuse through the use of EPCS.

Keywords

opioids electronic prescribing of controlled substances Medicare

Get full access to this article

View all access options for this article.

References

Angrist

J. D.

Pischke

J. S.

(2008). Mostly harmless econometrics: An empiricist’s companion. Princeton University Press.

Bao

Wen

Johnson

Jeng

P. J.

Meisel

Z. F.

Schackman

B. R.

(2018). Assessing the impact of State Policies for Prescription Drug Monitoring Programs on high-risk opioid prescriptions. Health Affairs, 37(10), 1596-1604. https://doi.org/10.1377/hlthaff.2018.0512

Buchmueller

Carey

(2018). The effect of Prescription Drug Monitoring Programs on opioid utilization in Medicare. American Economic Journal: Economic Policy, 10(1), 77-112. https://doi.org/10.1257/pol.20160094

Burger

(2018). The impact of cost on EPCS adoption. Point of Care Partners. https://www.pocp.com/hit-perspectives-cost-EPCS-Adoption

Centers for Medicare & Medicaid Services. (2018). Medicare fee-for-service provider utilization and payment data: Part D prescriber: Public use file: A methodological overview. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Downloads/Prescriber_Methods.pdf

Centers for Medicare & Medicaid Services. (2019). Medicare Part D Opioid Prescribing Mapping Tool Methodology. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Downloads/OpioidDrugList.zip

Congress. (2016). 21st Century Cures Act: H.R. 6. www.congress.gov/bill/114th-congress/house-bill/6?r=9

Conover

C. J.

Sloan

F. A.

(1998). Does removing certificate-of-need regulations lead to a surge in health care spending? Journal of Health Politics, Policy and Law, 23(3), 455-481. https://doi.org/10.1215/03616878-23-3-455

Coscelli

(2000). The importance of doctors’ and patient’s preferences in the prescription decision. Journal of Industrial Economics, 48(2), 349-369. https://doi.org/10.1111/1467-6451.00127

10.

Figge

H. L.

Fox

B. I.

Tribble

D. A.

(2009). Electronic prescribing of controlled substances. American Journal of Health-Systems Pharmacy, 66(14), 1311-1316. https://doi.org/10.2146/ajhp080597

11.

Friedman

A. S.

(2020). Smoking to cope: Addictive behavior as a response to mental distress. Journal of Health Economics, 72(July), Article 102323. https://doi.org/10.1016/j.jhealeco.2020.102323

12.

Friedman

M. A.

Schueth

Bell

D. S.

(2009). Interoperable electronic prescribing in the United States: A progress report. Health Affairs, 28(2), 393-403. https://doi.org/10.1377/hlthaff.28.2.393

13.

Grecu

A. M.

Dave

D. M.

Saffer

(2019). Mandatory access prescription drug monitoring programs and prescription drug abuse. Journal of Policy Analysis and Management, 38(1), 181-209. https://www.ncbi.nlm.nih.gov/pubmed/30572414

14.

Herbst

C. M.

Tekin

(2014). Child care subsidies, maternal health, and child-parent interactions: Evidence from three nationally representative datasets. Health Economics, 23(8), 894-916. https://doi.org/10.1002/hec.2964

15.

Hoagland

G. W.

Parekh

Swope

Bailie

Hart

LaBelle

Cafaro

C. S.

(2019). Tracking federal funding to combat the opioid crisis. https://bipartisanpolicy.org/wp-content/uploads/2019/03/Tracking-Federal-Funding-to-Combat-the-Opioid-Crisis.pdf

16.

Iizuka

(2012). Physician agency and adoption of generic pharmaceuticals. American Economic Review, 102(6), 2826-2858. https://doi.org/10.1257/aer.102.6.2826

17.

Johnson

Barker

Pylypchuk

Parasrampuria

(2019). Electronic prescribing of controlled substances among Medicare Part D Prescribers 2015-2016 (Data Brief No. 44). https://www.healthit.gov/sites/default/files/page/2019-04/SurescriptsPartDDataBrief_0.pdf

18.

Keele

Kelly

(2016). Dynamic models for dynamic theories: The ins and outs of lagged dependent variables. Political Analysis, 14(2), 186-205. https://doi.org/10.1093/pan/mpj006

19.

Lapane

K. L.

Quilliam

B. J.

Dore

D. D.

(2007). Roadblock on the health IT superhighway: E-prescribing and the Controlled Substances Act. Journal of Opioid Management, 3(4), 181-184. https://doi.org/10.5055/jom.2007.0002

20.

Lin

H. C.

Wang

Boyd

Simoni-Wastila

Buu

(2018). Associations between statewide Prescription Drug Monitoring Program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain. Addict Behaviors, 76(January), 348-354. https://doi.org/10.1016/j.addbeh.2017.08.032

21.

Madden

(2008). Sample selection versus two-part models revisited: The case of female smoking and drinking. Journal of Health Economics, 27(2), 300-307. https://doi.org/10.1016/j.jhealeco.2007.07.001

22.

Moyo

Simoni-Wastila

Griffin

B. A.

Harrington

Alexander

G. C.

Palumbo

Onukwugha

(2019). Prescription drug monitoring programs: Assessing the association between “best practices” and opioid use in Medicare. Health Service Research, 54(5), 1045-1054. https://doi.org/10.1111/1475-6773.13197

23.

National Academies of Sciences, Engineering, and Medicine. (2017). Pain management and the opioid epidemic: Balancing societal and individual benefits and risks of prescription opioid use. The National Academies Press.

24.

National Institute on Drug Abuse. (2019). Opioid summaries by state. https://www.drugabuse.gov/drugs-abuse/opioids/opioid-summaries-by-state

25.

National Institute on Drug Abuse. (2020). Drug use and its consequences increase among middle-aged and older adults. https://www.drugabuse.gov/news-events/nida-notes/2019/07/drug-use-its-consequences-increase-among-middle-aged-older-adults

26.

O’Neill

Kreif

Grieve

Sutton

Sekhon

J. S.

(2016). Estimating causal effects: Considering three alternatives to difference-in-differences estimation. Health Services and Outcomes Residence Methodology, 16(1-2), 1-21. https://doi.org/10.1007/s10742-016-0146-8

27.

Office of the National Coordinator for Health Information Technology. (2019). Connecting for impact: Linking Potential Prescription Drug Monitoring Programs (PDMPs) to patient care using health IT. https://www.healthit.gov/topic/health-it-health-care-settings/connecting-impact-linking-potential-prescription-drug-0

28.

Parasrampuria

Blanco

Barker

(2019). Electronic prescribing of controlled substances among office-based physicians, 2017 (Data brief No. 49). https://www.healthit.gov/sites/default/files/page/2019-09/officebasedphysicianelectronicprescribingofcontrolledsubstance2017.pdf

29.

Porterfield

Engelbert

Coustasse

(2014). Electronic prescribing: Improving the efficiency and accuracy of prescribing in the ambulatory care setting. Perspectives in Health Information Management, 11, Article 24808808. https://www.ncbi.nlm.nih.gov/pubmed/24808808

30.

Ross

J. M.

Yakovlev

P. A.

Carson

(2012). Does state spending on mental health lower suicide rates? Journal of Socio-Economics, 41(4), 408-417. https://doi.org/10.1016/j.socec.2010.10.005

31.

Rutkow

Chang

H. Y.

Daubresse

Webster

D. W.

Stuart

E. A.

Alexander

G. C.

(2015). Effect of Florida’s Prescription Drug Monitoring Program and Pill Mill Laws on opioid prescribing and use. JAMA Internal Medicine, 175(10), 1642-1649. https://doi.org/10.1001/jamainternmed.2015.3931

32.

Smith

V. A.

Maciejewski

M. L.

Olsen

M. K.

(2018). Modeling semicontinuous longitudinal expenditures: A practical guide. Health Service Research, 53 (Suppl. 1), 3125-3147. https://doi.org/10.1111/1475-6773.12815

33.

Thomas

C. P.

Kim

Kelleher

S. J.

Nikitin

R. V.

Kreiner

P. W.

McDonald

Carrow

G. M.

(2013). Early experience with electronic prescribing of controlled substances in a community setting. Journal of American Medical Informatics Association, 20(e1), e44-51. https://doi.org/10.1136/amiajnl-2012-001499

34.

Thomas

C. P.

Kim

McDonald

Kreiner

Kelleher

S. J.

Jr. Blackman

M. B.

Kaufman

P. N.

Carrow

G. M.

(2012). Prescribers’ expectations and barriers to electronic prescribing of controlled substances. Journal of American Medical Informatics Association, 19(3), 375-381. https://doi.org/10.1136/amiajnl-2011-000209

35.

Underwood

B. D.

(2018). I-STOP: Initiative of the Attorney General. https://ag.ny.gov/feature/i-stop

36.

U.S. Department of Health. (2018a). Electronic prescribing. https://www.health.ny.gov/professionals/narcotic/electronic_prescribing

37.

U.S. Department of Health. (2018b). Electronic prescribing of controlled substances requirements. Author.

38.

Wilson

Karsiia

Seth

Smith

IV. Davis

N. L.

(2020). Drug and opioid-involved overdose deaths—United States, 2017–2018. https://www.cdc.gov/mmwr/volumes/69/wr/mm6911a4.htm

39.

Yarbrough

C. R.

(2018). Prescription Drug Monitoring Programs produce a limited impact on painkiller prescribing in Medicare Part D. Health Service Research, 53(2), 671-689. https://doi.org/10.1111/1475-6773.12652